New therapeutic strategy to treat Alzheimer's

New therapeutic strategy to treat Alzheimer’s
From left to right, Laura López-Molina, Jordi Alberch, Albert Giralt, Anna Sancho-Balsells and Silvia Ginés, at the Faculty of Medicine and Health Sciences (UB). Credit: Universidad de Barcelona

Researchers from the Institute of Neurosciences of the University of Barcelona (UBNeuro) have identified a potential therapeutic strategy to treat Alzheimer's, according to a study published in Journal of Neuroscience. In a model of the illness in mice, astrocyte cells in the brain release proteins that favour survival of neurons. According to the researchers, these results are a step forward in the understanding of the physiology of astrocytes, and represent possible future therapies for Alzheimer's.

Alzheimer's disease is the most common form of dementia. Neurodegeneration in patients with this disease causes damage in memory and in other , sometimes combined with symptoms such as mood swings and personality changes. One of the most promising therapies against Alzheimer's is the use of neurotrophic factors, a family of proteins favouring neuron survival, such as brain-derived neurotrophic factor (BDNF). However, BDNF administration presents important challenges. For instance, it cannot be specifically targeted to the affected tissue or controlled to release the proper dosage, and high doses can be neurotoxic.

In this study, researchers studied BDNF generated by astrocytes, a type of star-shaped glial cell in the brain and the spinal cord. Astrocytes are affected by one of the neuroinflammation processes of Alzheimer's, astrogliosis, in which the glial fibrillary astrocytic protein (GFAP) and its coding gene are the most altered. The researchers designed an experiment with genetically induced Alzheimer's mice that produce BDNF protein depending on the GFAP levels. "With this design, from the moment neuroinflammation and pathology came up, the astrocytes could generate BDNF in the most affected areas of the sick brain. Therefore, the endogen reactions of the brain would regulate BDNF administration depending on the severity of the disease," says Albert Giralt, member of the Consolidated Research Group on Physiopathology of Neurodegenerative Diseases of the UB.

Effects of neuron formation and plasticity

The study shows this method restores the production and release of the neurotrophin in the sick neuronal tissue when the pathology starts. Then, the BDNF generated by astrocytes regulates neuron formation in samples of in vitro neuronal cultures and has cognitive effects in transgenic mice models. "These results show for the first time that astrocytes, so far regarded as neuronal, can produce BDNF and have the necessary molecular mechanisms to release it in the areas of the diseased tissue which requires activity to favour neuronal survival," says Albert Giralt.

The researchers also note that "the singularity of the design of the experiment enabled the astroglial cells to 'decide' when, where and what amount to produce and give BDNF to altered brain tissues." Therefore, "traits of the patient can mark endogenously and self-regulate the dose and other necessary therapeutic dynamics for a customized treatment."

Although the use of this therapy in humans is still far in the future, researchers note the use of astrocytes out of induced as a promising therapeutic strategy. "One possibility would be to derive induced stem cells from the skin of the patients, and then modify them genetically in vitro to express BDNF under the GFAP promoter. The last step would be to differentiate them and move them to the most altered brain regions of patients to boost survival and proper functioning of the existing neurons," says Albert Giralt.

This study makes it possible to apply neuroinflammation processes to other neurodegenerative diseases. "Our objective is, on the one hand, making this therapeutic approach plausible for the use in humans, and on the other, to present similar approaches for neurodegenerative diseases in which neuroinflammation is a main symptom," concludes the researcher.

Explore further

BDNF–VEGF interplay key to rapid antidepressant actions

More information: Benoit de Pins et al. Conditional BDNF delivery from astrocytes rescues memory deficits, spine density and synaptic properties in the 5xFAD mouse model of Alzheimer disease, The Journal of Neuroscience (2019). DOI: 10.1523/JNEUROSCI.2121-18.2019
Journal information: Journal of Neuroscience

Citation: New therapeutic strategy to treat Alzheimer's (2019, February 20) retrieved 28 January 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments